Trials / Completed
CompletedNCT05272683
Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy Subjects
An Open-label, Fixed-sequence, Drug-drug Interaction Study in Healthy Subjects to Evaluate the Effect of Itraconazole, a Strong CYP3A4 Inhibitor and Potent P-gp Inhibitor on the Pharmacokinetics of GLPG3667
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to determine the effect of itraconazole on the amount of GLPG3667 that gets into the blood when the 2 drugs are administered together compared to when GLPG3667 is administered alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG3667 | On day 1 and day 8, participants will receive a single dose |
| DRUG | Itraconazole | On days 5 to 11, participants will receive itraconazole once daily |
Timeline
- Start date
- 2022-02-28
- Primary completion
- 2022-04-01
- Completion
- 2022-04-22
- First posted
- 2022-03-09
- Last updated
- 2024-09-19
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT05272683. Inclusion in this directory is not an endorsement.